Inovio's vaccine candidate, INO-4800, is designed to generate an immune response system against the novel coronavirus by injecting DNA into a person. - iStock
US biotech firm Inovio on Tuesday reported encouraging results in preliminary clinical trials for its Covid-19 vaccine candidate.
The firm had administered the vaccine on 40 volunteers. According to the results, the vaccine candidate had triggered an immune system response in 94 per cent of the volunteers who had completed the phase one trial. The volunteers were given two shots four weeks apart, AFP reported.
Inovio's vaccine candidate, INO-4800, is designed to generate an immune ...
Read the full text thehindubusinessline